Navigation Links
Stem Cell Breakthrough May Lead to MS Treatments
Date:4/9/2009

Efforts produce human cells that might someday help repair damaged nerves

THURSDAY, April 9 (HealthDay News) -- U.S. scientists say they've coaxed human embryonic stem cells into generating cells that might someday be used to repair nerves damaged by multiple sclerosis.

The researchers pushed the stem cells to grow into critical nervous system support cells called oligodendrocytes, according to a report released Thursday.

Oligodendrocytes produce the myelin sheath that surrounds nerve fibers like wire insulation. The findings represent an important step toward embryonic stem cell-based therapies in general, experts say, and also for cell-based therapies for myelination disorders such as MS in particular. At the very least, the findings should lead to a laboratory model of the illness' pathology.

"They are definitely laying the groundwork for being able to apply these cells in terms of a therapeutic application," said Timothy Coetzee, executive director of Fast Forward, a wholly-owned subsidiary of the National Multiple Sclerosis Society, which partially funded the study.

Yet at the same time, he added, "It illustrated for me the critical importance of not assuming that because you can do something with a mouse cell, that a human cell is going to behave in the same manner."

The research was published in the May issue of the journal Development.

At the heart of this study is a fundamental question: What's the difference between mouse and man?

It's not as silly as it sounds. Human experimentation being both morally and legally forbidden, researchers often use model organisms such as mice as proxies for human development. The underlying assumption, of course, is that these organisms have fundamentally the same biology as we do. Sometimes, though, that assumption turns out to be wrong.

For years, researchers using mouse embryonic stem cells (ESCs) knew that if they added one of two proteins, FGF2 or SHH, to the cells' growth media, they could reliably induce those cells to become oligodendrocytes. The human application was obvious: ESC-derived oligodendrocytes could either be used directly as a cell therapy for MS and related diseases, or serve as research tools to study them.

But, when Dr. Su-Chun Zhang of the University of Wisconsin, Madison, who has been studying oligodendrocytes and myelination for nearly a quarter-century, tried to apply the culture conditions painstakingly worked out in rodents to human cells, oligodendrocytes failed to emerge.

"When we expand these [rodent] progenitor cells with FGF2 (and another factor called PDGF), these progenitor cells will become oligodendrocytes," Zhang said. But, "What we discovered was that when we did [the experiment] in the same way with human progenitor cells, they were blocked in this process."

By carefully dissecting the molecular events that occur as human ESCs differentiate first into neural stem cells, then neural progenitor cells, then pre-oligodendrocytes, and finally mature oligodendrocytes, Zhang and his team identified the source of the difference: While both rodents and humans control the process with the same regulatory circuitry and use the same molecules (including both FGF2 and SHH), FGF2 behaves differently in each species.

In mice, FGF2 promotes oligodendrocyte maturation; in humans, it inhibits the process.

"This finding is actually quite significant scientifically," said Zhang, "because even [though] the transcriptional network is more or less the same, yet they respond to the same factor in an opposite way. To me, that's quite extraordinary."

Once that simple fact was understood, the experiment could be tweaked so that human embryonic stem cells could, in fact, generate oligodendrocytes.

The study, said Coetzee, "just reinforces the absolute importance of being able to do some of this very fundamental biology and fundamental understanding of what human cells do, before you start experimenting with them to put them into people."

Dr. William Sheremata is professor of neurology at the University of Miami Miller School of Medicine. He sees many MS patients in his practice and called the study "an excellent example of work that is very carefully done by an expert group of people who really know what they are doing. So I think that the conclusion that FGF2 does not work to facilitate maturation of pre-oligodendrocytes is acceptable at face value. It is the first paper that has stated just that."

Sheremata questioned the therapeutic implications of the report, however, suggesting that therapies based on "autologous stem cells" (adult stem cells) were more likely to bear fruit.

Coetzee, though, called the findings "absolutely critical" to moving toward clinical applications for MS, whether directly by injection of mature oligodendrocytes or more primitive precursor cells, because it both enables researchers to grow large quantities of these cells and to molecularly define the process by which that happens.

"This actually begins to lay the foundation for envisioning having the ability to create the mass quantities of stem cells that you'd need in order to have a therapeutic application in MS," he said.

More information

For more on multiple sclerosis, visit the National Multiple Sclerosis Society.



SOURCES: Su-Chun Zhang, M.D., Ph.D., professor, anatomy and neurology, University of Wisconsin, Madison; Timothy Coetzee, Ph.D., executive director, Fast Forward, New York City; William Sheremata, M.D., professor, neurology, Miller School of Medicine, University of Miami; May 2009. Development


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
2. Hypnotherapy Breakthrough: Renowned Smoking Cessation Specialist Helps To Stop Smoking In One Session
3. Revolutionary Breakthrough in Lip Augmentation: Valencia Plastic Surgeon offers Permanent Lip Implants as Injectible Alternative
4. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
5. Blue Highway Selects Invention Machine Goldfire to Fuel Product Pipeline and Sustain Breakthrough Innovation
6. Breakthrough Solution Found in Refresh Skin Care Products
7. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
8. TB breakthrough could lead to stronger vaccine
9. Prosthetic Center of Excellence to Provide Breakthrough Technology to Rehabilitation Patients
10. Neurologist to Announce Breakthrough Headache Treatment
11. Nutrition 21 Launches Breakthrough Weight Management Product: Iceland Health(R) Appetite Control Formula
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem Cell Breakthrough May Lead to MS Treatments
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced that ... donate to Give To Cure’s campaign that is crowdfunding clinical trials to help find ... share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been ... user interface design and the developer has fixed known bugs within the app. Calls ... on their phone while not consuming any of their device’s battery power or memory. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LODI, N.J. , Feb. 4, 2016  Montoya ... Pinnacle Professional in the field of Pharmaceuticals. Montoya is ... . ... and supplies, Becton Dickinson provides healthcare institutions, ... medical equipment throughout fifty countries across the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... --> --> GAAP results: ... million, up $5.1 million or 4.1% from the third ... from the fourth quarter of 2014. Revenue for the ...
Breaking Medicine Technology: